BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cenomed BioSciences Presents Data on New Drug Candidates at the Society For Neuroscience in Washington DC


11/17/2008 10:00:45 AM

IRVINE, Calif.--(BUSINESS WIRE)--Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, Inc. (NASDAQ:ABII), today announced the presentation of results of research was presented at the 38th Annual Meeting of the Society for Neuroscience in Washington DC. This work has identified two lead compounds from the company's drug program with promise for the treatment of schizophrenia and post traumatic stress disorder (PTSD). The potential anti-psychotic, CM-2,303, has a unique mechanism of action and has shown positive data in pre-clinical models predicting effectiveness in the treatment of schizophrenia. This data was instrumental in the Company's recent decision to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin clinical testing of CM-2,303. “We will be conducting pre-clinical safety studies to satisfy FDA requirements for an IND and hope to begin a Phase 1 study of CM-2,303 exploring the drug's safety and efficacy in humans during the second half of 2009,” said Ernest Pfadenhauer, Vice President of Pharmaceutical Development of Cenomed BioSciences.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->